| abstract |
The present invention provides pharmaceutical compositions containing one or more unit doses for oral administration, each containing a therapeutically effective collooxygenase-2 selective low solubility inhibitor in water, wherein the compound is present in solid particles, of which the weight is particle size less than 1 µm, from 25% to 100%. The preparations are useful in the treatment or prevention of conditions or disorders caused by cyclooxygenase-2 and have particular advantages when it is desired to achieve a rapid onset of therapeutic effect. New crystalline forms of celecoxib, Form I and Form II, are described. These crystalline forms have unique chemical and physical properties over other solid forms of celecoxib and are characterized by diffraction images obtained by x-ray powder diffraction (PXRD), thermograms obtained by differential scanning calorimetry (DSC) and other physical characterizations. |